CLINICAL TRIALS PROFILE FOR DICHLORPHENAMIDE

« Back to Dashboard

All Clinical Trials for dichlorphenamide

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004802 ↗	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders	Completed	Ohio State University	Phase 3	1992-06-01	OBJECTIVES: I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic paralysis, and hypokalemic periodic paralysis.
NCT00004802 ↗	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders	Completed	National Center for Research Resources (NCRR)	Phase 3	1992-06-01	OBJECTIVES: I. Assess the efficacy of dichlorphenamide in the treatment of episodic weakness attacks in patients with hyperkalemic periodic paralysis, paramyotonia congenita with periodic paralysis, and hypokalemic periodic paralysis.
NCT00494507 ↗	Hyper- and Hypokalemic Periodic Paralysis Study	Completed	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 3	2007-06-01	The purpose of this study is to compare Dichlorphenamide with placebo (an inactive substance) for prevention of episodes and for improvement of strength in hyperkalemic (HYP) and hypokalemic (HOP) periodic paralysis. This study will also look at the long-term effects of Dichlorphenamide in periodic paralysis.
NCT00494507 ↗	Hyper- and Hypokalemic Periodic Paralysis Study	Completed	University of Rochester	Phase 3	2007-06-01	The purpose of this study is to compare Dichlorphenamide with placebo (an inactive substance) for prevention of episodes and for improvement of strength in hyperkalemic (HYP) and hypokalemic (HOP) periodic paralysis. This study will also look at the long-term effects of Dichlorphenamide in periodic paralysis.

Clinical Trial Conditions for dichlorphenamide

Condition Name

Condition Name for dichlorphenamide
Intervention	Trials
Hypokalemic Periodic Paralysis	2
Hyperkalemic Periodic Paralysis	1
Paralysis, Hyperkalemic Periodic	1
Paramyotonia Congenita	1

Condition MeSH

Condition MeSH for dichlorphenamide
Intervention	Trials
Paralysis	2
Hypokalemic Periodic Paralysis	2
Paralysis, Hyperkalemic Periodic	2
Myotonic Disorders	1

Clinical Trial Locations for dichlorphenamide

Trials by Country

Trials by Country for dichlorphenamide
Location	Trials
United States	8
United Kingdom	1
Italy	1

Trials by US State

Trials by US State for dichlorphenamide
Location	Trials
Texas	1
Ohio	1
New York	1
Missouri	1
Minnesota	1

Clinical Trial Progress for dichlorphenamide

Clinical Trial Phase

Clinical Trial Phase for dichlorphenamide
Clinical Trial Phase	Trials
Phase 3	2

Clinical Trial Status

Clinical Trial Status for dichlorphenamide
Clinical Trial Phase	Trials
Completed	2

Clinical Trial Sponsors for dichlorphenamide

Sponsor Name

Sponsor Name for dichlorphenamide
Sponsor	Trials
Ohio State University	1
National Center for Research Resources (NCRR)	1
National Institute of Neurological Disorders and Stroke (NINDS)	1

Sponsor Type

Sponsor Type for dichlorphenamide
Sponsor	Trials
Other	2
NIH	2

Dichlorphenamide clinical trials update, market analysis and forecast: pipeline status, competitive landscape, and revenue projection

Last updated: August 1, 2026

No current, verifiable market authorization status, FDA/EMA regulatory status, or active clinical-trial identifiers for dichlorphenamide were provided in the request. Without authoritative, source-backed inputs (trial registries, labeled indications, approvals, and sales/reimbursement data), a complete and accurate clinical-trials update and market projection cannot be produced.

What is dichlorphenamide’s current clinical development status and which trials are active?

Answer: Not provided.

Which indications have ongoing dichlorphenamide Phase 1–3 trials?

Answer: Not provided.

What are the trial identifiers (NCT/EudraCT) and recruitment statuses?

Answer: Not provided.

What is the regulatory status of dichlorphenamide in the US and Europe?

Answer: Not provided.

What is the FDA approval status of dichlorphenamide and its labeled indication(s)?

Answer: Not provided.

What is the EMA status and any orphan-designation or similar incentives?

Answer: Not provided.

What is the competitive landscape for dichlorphenamide by mechanism and target patient population?

Answer: Not provided.

Which branded and generic alternatives compete with dichlorphenamide?

Answer: Not provided.

How does dichlorphenamide compare with acetazolamide and other carbonic anhydrase inhibitors?

Answer: Not provided.

How does dichlorphenamide’s market size evolve and what drives demand?

Answer: Not provided.

What are the key demand drivers (incidence, treatment guidelines, payer coverage)?

Answer: Not provided.

What are the key constraints (safety profile, adherence, administration, monitoring)?

Answer: Not provided.

What revenue forecast is possible for dichlorphenamide through 2035?

Answer: Not provided.

What baseline sales assumptions are required for the forecast?

Answer: Not provided.

What scenarios change the projection (new indication, label expansion, generic entry)?

Answer: Not provided.

When does dichlorphenamide face generic entry or exclusivity loss?

Answer: Not provided.

What Orange Book patents and exclusivities apply to dichlorphenamide?

Answer: Not provided.

Are there Paragraph IV challenges or settlements affecting launch timelines?

Answer: Not provided.

Key Takeaways

Answer: Not provided.

FAQs

1. What are the latest dichlorphenamide trial results by endpoint and timeline? Not provided.
2. Is dichlorphenamide approved for any specific rare condition or orphan indication? Not provided.
3. Which companies are developing competing carbonic anhydrase inhibitor therapies? Not provided.
4. What is the risk of generic or biosimilar-like competition for dichlorphenamide? Not provided.
5. How do safety monitoring requirements affect real-world use and revenue? Not provided.

References

No sources were provided or verifiably cited.